2023 - The Forefront of Radiopharmaceuticals: History of α-Emitters with a Focus on Radiobiology, Physics, and Clinical Considerations

In an upcoming webinar, Medpace Radiation Oncologist, Radiation Clinical Pharmacologist, are joined by biotech Molecular Imaging Director, and Academic Medical Physicist to cover considerations in α-particle therapy.
While alpha emitter isotope therapy, radium, has been available for over a hundred years, there is renewed promise for targeted alpha therapy in treating advanced and metastatic tumors. There are recent reports showing impressive safety and tumor response with α-particle therapy across many solid tumor populations.
In this webinar, Medpace will review:
History of alpha emitting radionuclides
Radiobiologic considerations for Ra-223, Actinium 225, Lead 212
Concepts for radiation planning and personalized dosimetry
Optimal approaches for pharmacokinetics and
Medical considerations necessary to design a successful α-RPT clinical trial
Register today to hear from Jess Guarnaschelli, MD, Radiation Oncology Senior Medical Director, Jason Anderson Medpace Clinical Pharmacologist, Biostatistician; Michael A. Lamba, PhD, Medical Physicist, University of Cincinnati College of Medicine, and A. Omer Nawaz, Ph.D., Senior Director of Radiation Sciences and Molecular Imaging, Fusion Pharmaceuticals, to discuss the emerging developments in dosimetry, radiopharmaceuticals, radiation therapy, and radiation oncology.
Click here to learn more about Medpace’ s radiation therapy, radiopharmaceutical, and radiation oncology solutions.